Abstract
Abstract
Objectives
Uncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface.
Methods
Six online discussions among WG members (Dec 2021–Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions.
Results
The WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: “unavailable,” “inaccurate,” “conflicting,” “not understandable,” “random variation,” “information,” “prediction,” “impact,” “risk,” “relevance,” “context,” and “judgment.” These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed.
Conclusions
The systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.
Publisher
Cambridge University Press (CUP)
Reference43 articles.
1. 36. Agrawal, S , Arora, S , Amiri-Kordestani, L , et al. Use of single-arm trials for US Food and Drug Administration Drug approval in oncology, 2002–2021. JAMA Oncol [Internet]. 2022;9:266-272 [cited 2023 Jan 5]; Available from https://doi.org/10.1001/jamaoncol.2022.5985.
2. 37. Bloem, LT , Bot, RE , Mantel‐Teeuwisse, A , et al. Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs; 2021; Available from: https://www.semanticscholar.org/paper/073a48b0c721d44fc7b0bfbd064689ec1a495bd5.
3. Varieties of uncertainty in health care: A conceptual taxonomy;Han;Med Decis Mak Int J Soc Med Decis Mak.,2011
4. Aleatoric and epistemic uncertainty in groundwater flow and transport simulation;Ross;Water Resour Res [Internet],2009
5. 29. Introduction to Health Technology Evaluation | NICE Health Technology Evaluations: The Manual | Guidance | NICE [Internet]. NICE; [cited 2022 Aug 3]. Available from: https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献